Molecular targets in pituitary tumours

Nature Reviews Cancer

Volumn 4, Issue 4, 2004, Pages 285-295

  Heaney, Anthony P ^a   Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23023; BIM 23120; BIM 23206; BIM 23454; BIM 23A387; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH FACTOR; LIGAND; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PERGOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINAGOLIDE; RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ABDOMINAL DISCOMFORT; ACUTE PSYCHOSIS; CANCER INHIBITION; CELL TYPE; CHEMOTHERAPY INDUCED EMESIS; CHIMERA; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DOPAMINERGIC ACTIVITY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; GALLSTONE; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS FUNCTION; HYPOPHYSIS TUMOR; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEIN TARGETING; RETROPERITONEAL FIBROSIS; REVIEW; TUMOR CELL; TUMOR VOLUME; VASOSPASM;

EID: 1942469957     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1320     Document Type: Review

References (99)

1. Melmed, S. & Kleinberg, D. in Williams Textbook of Endocrinology 10th edn Ch. 8 (eds Larson, P. R., Kronenberg, H. M., Melmed, S. & Polonsky, K. S.) 177-279 (W. B. Saunders, Philadelphia, 2003). Comprehensive and up-to-date background information on pituitary structure and function.
2. Melmed, S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest. 112, 1603-1618 (2003).
3. Sano, K. Incidence of primary tumors (1969-1983) in Brain Tumor Registry of Japan. Neurol. Med. Chir. 37, 391-441 (1992).
4. Schlechte, J. A. Clinical impact of hyperprolactinaemia. Baillieres Clin. Endocrinol. Metab. 9, 359-366 (1995).
5. Molitch, M. E. Medical management of prolactin-secreting pituitary adenomas. Pituitary 5, 55-65 (2002).
6. Molitch, M. E. in The Pituitary 2nd edn (ed. Malden, M. A.) 455-495 (Blackwell Publishing, 2002)
7. Nabarro, J. D. Acromegaly. Clin. Endocrinol. 26, 481-512 (1987).
8. Miller, G. M. et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. 80, 1386-1392 (1995).
9. Larsson, C., Skogseid, B., Oberg, K., Nakamura, Y. & Nordenskjold, M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 322, 85-87 (1998).
10. Chandrasekharappak, S. C. et al. Positional cloning of the gene for multiple endocrine neoplasla-type 1 Science 276, 404-406 (1997). Describes the menin gene, which is one of the few characterized genes associated with familial pituitary-tumour syndromes.
11. Casey, M. et al. Mutations in the protein kinase A R1α regulatory subunit cause familial cardiac myxomas and Carney complex. J. Clin. Invest. 106, R31-R38 (2000).
12. Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type 1-α regulatory subunit in patients with Carney complex. Nature Genet. 26, 89-92 (2000).
13. Dotsch, J. et al. Gs α mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year old boy with McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 81, 3839-3842 (1996).
14. Asa, S. L. & Ezzat, S. The pathogenesis of pituitary tumors. Nature Rev. Cancer 2, 836-849 (2002).
15. Alexander, J. M. et al. Clinically non-functioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86, 336-340 (1990).
16. Herman, V., Fagin, J., Gonsky, R., Kovacs, K. & Melmed, S. Clonal origins of pituitary adenomas. J. Clin. Endocrinol. Metab. 71, 1427-1433 (1990). Seminal paper demonstrating that pituitary tumours are monoclonal expansions.
17. Thorner, M. O. et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth-hormone-releasing factor. J. Clin. Invest. 70, 965-977 (1982).
18. Sano, T., Asa, S. L. & Kovacs, K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr. Rev. 9, 357-373 (1988).
19. Lyons, J. et al. Two G protein oncogenes in human endocrine tumors. Science 249, 655-659 (1990). Describes the most common genetic mutation that is detected in sporadic pituitary tumours.
20. Spada, A. & Vallar, L. G-protein oncogenes in acromegaly. Horm. Res. 38, 90-93 (1992).
21. Zhang, X. et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 84, 761-767 (1999).
22. Heaney, A. P. et al. Early involvement of estrogen-induced pituitary tumor transforming gene (PTTG) and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Med. 5, 1317-1321 (1999).
23. Shimon, I. & Melmed, S. Management of pituitary tumors. Ann. Intern. Med. 129, 472-483 (1998).
24. Greenman, Y. & Melmed, S. Diagnosis and management of non-functioning pituitary tumors. Ann. Rev Med. 47, 95-106 (1996).
25. Mamoalam, T. J., Tyrrell, J. B. & Wilson, C. B. Transsphenoidal microsurgery for Cushing's disease: a report of 216 cases. Ann. Intern. Med. 109, 487-493 (1988).
26. Simmons, N. E., Alden, T. D., Thorner, M. O. & Laws, E. R. Jr. Serum cortisol response to transphenoidal surgery for Cushing disease. J. Neurosurg. 95, 1-8 (2001).
27. Hoybye, C. et al. Adrenocorticotrophic hormone-producing pituitary tumors: 12 to 22-year follow-up after treatment with sterotactic radiosurgery. Neurosurgery 49, 284-291 (2001).
28. Swearingen, B. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419-3426 (1998).
29. Freda, P. U., Wardlaw, S. L. & Post, K. D. Long-term endocrinologic follow-up after transsphenoidal surgery for acromegaly. J. Neurosurg. 89, 353-358 (1998).
30. Ebersold, M. J., Quast, L. M., Laws, E. R., Scheithauer, B. & Randall, R. V. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J. Neurosurg. 64, 713-719 (1986).
31. Brada, M. et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol. 38, 571-578 (1993).
32. Barrande, G. et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J. Clin. Endocrinol. Metab. 85, 3779-3785 (2000).
33. Erfurth, E. M., Bulow, B., Mikoczy, Z. & Hagmar, L. Incidence of a second tumor in hypopituitary patients operated for pituitary tumors. J. Clin. Endocrinol. Metab. 86, 659-662 (2001).
34. Freda, P. U. & Wardlaw, S. L. Primary medical therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3031-3033 (1998).
35. Orth, D. N. Cushing's syndrome. N. Engl. J. Med. 332, 791-803 (1995).
36. Reubi, J. C. et al. Somatostatin receptors in human endocrine tumours. Cancer Res. 47, 551-558 (1987).
37. Casini-Raggi, C. et al. Somatostatin receptors in non-endocrine tumors. Minerva Endocrinol. 26, 149-158 (2001).
38. Shimon, I. et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J. Clin. Invest. 100, 2386-2392 (1997).
39. Greenman, Y. & Melmed, S. Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 78, 398-403 (1994).
40. Ballare, E. et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86, 3809-3814 (2001).
41. Melmed, S. Acromegaly. N. Engl. J. Med. 5, 966-977 (1990).
42. Lamberts, S. W., van Der Lely, A. J., de Herder, W. W. & Hofland, L. J. Octreotide. N. Engl. J. Med. 334, 246-254 (1994).
43. Lamberts, S. W. J. et al. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue 201-995 in patients with prolactinomas and acromegaly. Clin. Endocrinol. 25, 201-212 (1986). Classical description of the developmental history and early use of somatostatin analogues.
44. Ezzat, S. et al. Octreotide treatment of acromegaly. A randomized multicenter study. Ann. Intern. Med. 117, 711-718 (1992).
45. Newman, C. B. et al. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J. Clin. Endocrinol. Metab. 80, 2768-2775 (1995).
46. Vance, M. L. & Harris, A. G. Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of a multicenter acromegaly study group. Arch. Int. Med. 151, 1573-1578 (1991).
47. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J. Endocrinol. Invest. 20, 424-428 (1997).
48. Colao, A. et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab. 86, 2779-2786 (2001).
49. Baldelli, R. et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J. Clin. Endocrinol. Metab. 85, 4099-4103 (2000).
50. Freda, P. U. Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87, 3013-3018 (2002).
51. Hofland, L. J. & Lamberts, S. W. The pathophysiological consequences of somatostatin receptor internalisation and resistance. Endocr. Rev. 24, 28-47 (2003).
52. Melmed, S. et al. Consensus: guidelines for acromegaly management. J. Clin. Endocrinol. Metab. 87, 4054-4058 (2001).
53. Patel, Y. et al. Molecular biology of somatostain receptor subtypes. Metabolism 45, 31-38 (1996).
54. Culler, M. D., Taylor, J. E. & Moreau, J. P. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann. Endocrinol. 83, 2S5-12 (2002).
55. Ren, S. G. et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endo. Metab. 88, 4239-4245 (2003).
56. Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G. & Weckbecker, G. SOM230: a novel somatostatin peptidomimentic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707-716 (2002).
57. th Annual Meeting of The Endocrine Society P2-449 (2003).
58. th Annual Meeting of The Endocrine Society P1-625 (2003).
59. th Annual Meeting of The Endocrine Society 58-56 (2002).
60. Weckbecker, G., Briner, U., Lewis, I. & Bruns, C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology, 143, 4123-4130 (2002).
61. Sharma, K. & Srikant, C. B. Int. J. Cancer. 76, 259-266 (1998).
62. Pakes, D. Drug therapy: bromocriptine. N. Engl. J. Med. 301, 873-878 (1979).
63. Besser, G. M., Parke, L., Edwards, C. R., Forsyth, I. A. & McNeilly, A. S. Galactorrhoea: successful treatment with reduction of prolactin levels by brom-ergocryptine. Br. Med. J. 3, 669-672 (1972). First paper to describe the use of D2-agonist therapy for prolactin-secreting tumours.
64. Vance, M. L., Evans, W. S. & Thorner, M. O. Drugs five years later. Bromocriptine. Ann. Intern. Med. 100, 78-91 (1984).
65. Klibanski, A. & Zervas, N. T. Diagnosis and management of hormone-secreting pituitary adenomas, N. Engl. J. Med. 324, 822-831 (1991).
66. Bevan, J. S., Webster, J., Burke, C. W. & Scanlon, M. F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13, 220-240 (1992).
67. Kleinberg, D. L. et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N. Engl. J. Med. 309, 704-709 (1983).
68. Vance, M. L. et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann. Intern. Med. 112, 668-673 (1990).
69. Bevan, J. S. & Davis, J. R. Cabergoline: an advance in dopaminergic therapy. Clin. Endocrinol. 41, 709-712 (1994).
70. Colao, A. et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82, 876-883 (1997).
71. Webster, J. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904-909 (1994).
72. Cunningham, B. C. et al. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825 (1991).
73. Kopchick, J. J., Parkinson, C., Stevens, E. C. & Trainer, P. J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623-646 (2002). Describes the developmental molecular rationale and mechanism of action of growth-hormone-receptor antagonists.
74. Kohn, D. T. & Kopchick, J. J. Growth hormone receptor antagonists. Minerva Endocrinol. 27, 287-298 (2002).
75. Frank, S. J. Receptor dimerization in GH and erythropoietin action: it takes two to tango. Endocrinology 143, 2-10 (2002)
76. Trainer, P. J. et al. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N. Eng. J. Med. 309, 1495-1501 (2000).
77. Bonert, V. S., Zib, K., Scarlett, J. A. & Melmed, S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs J. Clin. Endocrinol. Metab. 85, 2958-2961 (2000).
78. van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 358, 1754-1759 (2001).
79. Sheppard, M. C. Primary medical therapy for acromegaly. Clin. Endocrinol. 58, 387-399 (2003).
80. Flogstad, A. K. et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J. Clin. Endocrinol. Metab, 79, 461-465 (1994).
81. Saveanu, A. et al. Demonstration of enhanced potency of a chlmeric somatostain-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87, 5545-5552 (2002).
82. Ren, S. G. et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab. 11, 5414-5421 (2003).
83. Musset, F., Bertrand, P., Kordon, C. & Enjalbert, A. Differential coupling with pertussis toxin-sensitive G proteins of dopamine and somatostatin receptors involved in regulation of adenohypophyseal secretion. Mol. Cell Endocrinol, 73, 1-10 (1990).
84. Rocheville, M. et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (2000). First paper to demonstrate heterodimerization of the G-protein-coupled dopamine and somatostatin receptors.
85. Forman, B. M. et al. 15-Deoxy-δ 12,14-prostaglandin J1 is a ligand for the adipocyte determination factor PPAR γ. Cell 83, 803-812 (1995).
86. Elstner, E. et al. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl Acad. Sci. USA 95, 8806-8811 (1988).
87. Kubota, T. et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent anti-tumor effects against prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352 (1998).
88. Heaney, A. P., Fernando, M., Yong, W. & Melmed, S. Functional PPAR-γ receptor represents a novel therapeutic target in Cushing's disease. Nature Med. 11, 1281-1287 (2002).
89. Heaney, A. P., Fernando, M. & Melmed, S. PPAR-γ receptor ligands: a novel therapy for pituitary tumors. J. Clin. Invest. 111, 1381-1388 (2003).
90. Nieman, L. Medical therapy of Cushing's disease. Pituitary 5, 77-82 (2003).
91. Gudas, L. J., Spom, M. B. & Roberts, A. B. in The Retinoids: Biology, Chemistry, and Medicine. (eds Spom, M. B., Roberts, A. B. & Goodman, D. S.) 443-520 (Raven, New York, 1994).
92. Pitha-Rowe, I., Petty, W. J., Kitareewan, S. & Dmitrovsky, E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 17, 1723-1730 (2003).
93. Kurie, J. M. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr. Opin. Oncol. 11, 497-502 (1999). Good review of rationale and potential therapeutic use of retinoids in cancer.
94. Rizvi, N. A. et al. A phase I study of LGD1069 in adults with advanced cancer. Clin. Cancer Res. 5, 1658-1664 (1999).
95. Koeffler, H. P. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9, 1-9 (2003).
96. Paez-Pereda, M. et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 108, 1123-1131 (2001).
97. Colombo, P. et al. Effects of long-term treatment with the gonadotrophin-releasing analog nafarelin in patients with non-functioning pituitary adenomas. Eur. J. Endocrinol. 130, 339-345 (1994).
98. Schally, A. V. & Nagy, A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life. Sci. 11, 2305-2320 (2003).
99. Horwitz, G. A., Miklovsky, I., Heaney, A. P., Ran, S. G. & Melmed S. Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol. Endocrinol. 17, 600-609 (2003)